RxDoctor Payments Data

Carrie Davis, MD

Ophthalmology · Beachwood, OHNPI 1447220199

Payments from drug & device makers

$1,603in general payments, 2019–2025

Across 74 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$407
  • Oyster Point Pharma, Inc.$248
  • Glaukos Corporation$150
  • AbbVie$126
  • Sun Pharmaceutical Industries Inc.$107
  • Alcon$98
  • plus $468 from 12 others

What the payments were for

  • Food & beverage$1,57298%
  • Education$141%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,603 in reported general payments places this provider in the 55th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$122,801
Medicare patients
545
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$53,212
LumiganBimatoprost21$13,060
Cyclosporine22$8,724
Latanoprost460$4,979
Bimatoprost13$2,294
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat144$2,146
Timolol Maleate144$1,493
Prednisolone Acetate43$1,114
Ketorolac Tromethamine20$637
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha71$558
Brimonidine Tartrate82$554
Dorzolamide Hcl31$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$126$66,27364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Beachwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →